Firering Strategic Minerals: From explorer to producer. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
A big research project released in August between Sensyne and Bayer. Also by the way there are a number of Sensyne employees working remotely from Germany from their LinkedIn info.
https://arxiv.org/pdf/2208.01607.pdf
Does this bode well for future collaboration?
Page 21 ‘acknowledgments’
That research was submitted here on 2nd https://arxiv.org/abs/2208.01607
This doesn't sound good, let's see how this pans out?
https://www.bindmans.com/knowledge-hub/news/bindmans-advises-medconfidential-as-nhs-trusts-share-patient-data-with-sensyne-health/
I think you will find that is some ‘do good’ protest type organisation focused on ‘human rights’. We will see if Sensyne can carry the NHS with it. There is still a lot to ‘win’ here. It cannot be too long before we see the year end April 22 results published on Companies House website and perhaps some encouraging news on progress since Alex Snow has taken over. There is already some details with a statement from an August board meeting on cash status and divestment proceedings within the accounts for the divisions published at Companies House.
That was also published in May 22 at the height of negative publicity towards the company
Last year.
https://gatemore.com/wp-content/uploads/2021/07/Gatemore-Letter-to-Sensyne.pdf
Since then a lot has changed.
I would suggest this Co under Alex Snow may have undergone / still undergoing rapid reorganisation. We know the board, now only consists of 4 and some senior management positions have also been axed. With Concentration on RWD, a completely revamped Co could emerge, worthy of a sale at a good price when the time is right.
After all, whilst one division was heavily loss making, one division had a £22m profit with a NAV of £80 odd million. Then of course we have the loan note debt to consider and it looks like conversion into shares may take place in January depending on the holders of these loan notes That’s when the dilution occurs